ArticleWorld journal of microbiology & biotechnology2026
A dual-functional dendrimer-based system integrating recombinant endolysin and cinnamic acid for enhanced endolysin stability and antibacterial activity against Acinetobacter baumannii.
Article in World journal of microbiology & biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The application of recombinant endolysins against Gram-negative bacteria is often limited by their stability and the protective barrier presented by the outer membrane. In this study, we developed a dual-component magnetic nanoplatform to address these challenges. Third-generation poly(amidoamine) (PAMAM)-functionalized superparamagnetic iron oxide nanoparticles (SPIONs) were employed for PlyF307 immobilization (PlyF307-immobilized G3 PAMAM-SPIONs, G3E), while an analogous cinnamic acid-functionalized G3 PAMAM-SPION platform (G3Cin) was prepared to provide additional antimicrobial activity and potentially influence interactions with the bacterial envelope. Immobilized PlyF307 retained 92.7% of its initial activity, with optimal performance at pH 8 and 30 °C. The combined G3E + G3Cin system reduced the viability of Acinetobacter baumannii by approximately 2 log₁₀ from an initial concentration of 1.0 × 10⁶ CFU/mL and exhibited greater antibacterial activity than the individual treatments. Physicochemical characterization (VSM, FTIR, DLS, zeta potential, and SEM) confirmed successful functionalization and provided complementary information on the nanoparticle properties. Overall, the dual-component SPION-based platform improved the functional stability and antibacterial performance of immobilized PlyF307, highlighting its potential for antimicrobial nanobiotechnology applications.
Indexed as
Identifiers
42726361What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.